ALPS ADVISORS INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 204 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.

Quarter-by-quarter ownership
ALPS ADVISORS INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$343,800
-20.9%
9,000
+17.8%
0.00%
-25.0%
Q4 2022$434,602
+43.4%
7,638
-0.4%
0.00%
+33.3%
Q3 2022$303,000
-15.8%
7,669
-14.4%
0.00%
-25.0%
Q4 2021$360,000
+0.8%
8,959
+2.1%
0.00%
+33.3%
Q3 2021$357,000
-92.1%
8,779
-97.0%
0.00%
-91.4%
Q3 2019$4,525,000
-13.2%
291,765
-3.8%
0.04%
-10.3%
Q2 2019$5,212,000
-7.6%
303,357
-13.4%
0.04%
-2.5%
Q1 2019$5,640,000
+6.8%
350,310
-3.0%
0.04%
-2.4%
Q4 2018$5,282,000
+2.6%
361,008
+27.4%
0.04%
+20.6%
Q3 2018$5,149,000
+32.9%
283,377
+23.4%
0.03%
+36.0%
Q2 2018$3,873,000
-8.0%
229,566
+6.8%
0.02%
-24.2%
Q1 2018$4,209,000
+31.7%
214,857
+36.2%
0.03%
+50.0%
Q4 2017$3,196,000
+31.6%
157,748
+12.9%
0.02%
+29.4%
Q3 2017$2,428,000
+50.1%
139,764
+10.7%
0.02%
+54.5%
Q2 2017$1,618,000
+12.0%
126,208
+13.3%
0.01%
+10.0%
Q1 2017$1,444,000
+17.5%
111,401
-10.5%
0.01%
+11.1%
Q4 2016$1,229,000
-38.3%
124,438
-24.6%
0.01%
-43.8%
Q3 2016$1,993,000
+27.3%
164,982
-9.0%
0.02%
+14.3%
Q2 2016$1,565,000
+15.8%
181,353
+27.1%
0.01%0.0%
Q1 2016$1,351,000
-53.8%
142,665
-15.4%
0.01%
-51.7%
Q4 2015$2,923,000
-89.1%
168,639
-15.3%
0.03%
+3.6%
Q3 2015$26,751,000
+838.0%
199,192
+57.7%
0.03%
+16.7%
Q2 2015$2,852,000
+220.4%
126,319
+102.7%
0.02%
+242.9%
Q1 2015$890,00062,3100.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2019
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders